业绩总结 - 2025年第一季度收入增长24%，达到2250万美元[10] - 排除2024年NAUTILUS研究中的植入物，RNS系统收入增长29%[10] - 2024年预计收入增长超过20%[9] - 2025年第一季度实际收入为2250万美元，同比增长24%[71] - 2025年收入指导范围为9300万至9700万美元，预计同比增长16%至21%[71] - 公司毛利率为77%，预计在73%至75%之间[71] 用户数据 - RNS系统在植入后36个月内，患者的中位数癫痫发作频率减少82%[31] - RNS系统的临床研究显示，9年后患者的中位数癫痫发作减少75%[26] - 1/3的癫痫患者为药物难治性癫痫（DRE）[14] - 每年约有5万名DRE患者被送入综合癫痫中心[40] - 40%的难治性癫痫(DRE)患者患有广泛性癫痫[57] 市场展望与扩张 - 美国可寻址市场超过550亿美元，核心市场年机会超过20亿美元[9] - 预计未来将扩大市场，进入广泛的癫痫和儿童局灶性患者群体[9] - 计划在2025年将RNS系统的植入和转诊数量翻倍，目标是扩展到1800名癫痫专家和所有功能性神经外科医生[53] - 公司致力于扩大RNS系统的适应症，计划在2024年启动社区扩展活动[61] - 2024年将进行试点活动，2025年计划扩展项目[63] 研发与新技术 - RNS活跃开处方医生数量创下新高[10] - NAUTILUS试验的植入和随访已完成，预计在2025年3月完成一年的随访[58] - 公司专注于提高RNS系统的利用率和采用率，以推动长期增长[72] 财务状况 - 截至2025年3月31日，公司总现金余额为6630万美元[69]

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, ...

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace’s term loan with CRG Partners IV, L.P., with proceeds of the new revolving ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, ...

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, 2 ...

NeuroPace (NPCE) recently announced promising preliminary one-year results from its pivotal NAUTILUS trial, evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). This study marks a major milestone, as it is the first to assess a brain-responsive neuromodulation system in this patient population.This development positions NeuroPace as a leader in advancing neuromodulation therapies for generalized epilepsy, a segment historically underserved by current medical technologies. With t ...

NeuroPace, Inc. NPCE released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE).The study met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure.The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to s ...

NeuroPace (NPCE) Update / Briefing May 27, 2025 08:30 AM ET Speaker0 Greetings. Welcome to the Neuropace Update Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to Scott Schafer, Head of Investor Relations. Thank you. You may begin. Speaker1 Good morning and thank you for joining today's conference call. On the call, we will hear from Joel Becke ...

-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, ...

NeuroPace (NPCE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Jeremy Feffer - Managing DirectorJoel Becker - CEO & Board MemberRebecca Kuhn - CFO & VP of Finance and AdministrationMike Kratky - Senior Managing Director - Medical Devices & TechnologyNelson Cox - Equity Research AssociatePriya Sachdeva - Director - Equity ResearchRohin Patel - Vice President Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsMike Polark - Senior Equity Re ...